Wu Ming, Chen Mengjuan, Zhao Yuzhen, Zhang Xijun, Ding Xiao, Yuan Jianjun, Shi Jinjin, Yu Wenyan, Zhu Haohui
Department of Ultrasonography, Henan Provincial People's Hospital, Zhengzhou, 450003, China.
School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, 450001, China.
Small Methods. 2025 Mar 20:e2402019. doi: 10.1002/smtd.202402019.
Atherosclerosis (AS), a chronic inflammatory disease and a leading cause of cardiovascular morbidity and mortality worldwide, is a significant contributor to disability. Neutrophil extracellular traps (NETs) have been closely associated with the progression of AS and plaque vulnerability. However, developing a treatment strategy that specifically targets neutrophils and effectively reduces NET release at the lesion site remains a major challenge. In this study, a biomimetic nanosystem with neutrophil-targeting properties is engineered. Coating Prussian blue nanoparticles with bacterial biomimetic membranes (MPB NPs) enables specific recognition and internalization by neutrophils. By hitching onto neutrophils, the MPB NPs scavenge intracellular reactive oxygen species (ROS) and suppress NET formation at the lesion site. Importantly, MPB NPs reduce the size of atherosclerotic plaques by 3.29-fold, from 22.53% to 6.85%, stabilize the plaques, and halt their progression in atherosclerotic mouse models. These findings suggest that MPB NPs offer a promising therapeutic strategy for atherosclerosis, and provide a versatile platform for the treatment of NET-associated diseases.
动脉粥样硬化（AS）是一种慢性炎症性疾病，也是全球心血管疾病发病和死亡的主要原因，是导致残疾的重要因素。中性粒细胞胞外陷阱（NETs）与AS的进展和斑块易损性密切相关。然而，开发一种专门针对中性粒细胞并有效减少病变部位NET释放的治疗策略仍然是一项重大挑战。在本研究中，设计了一种具有中性粒细胞靶向特性的仿生纳米系统。用细菌仿生膜包覆普鲁士蓝纳米颗粒（MPB NPs）可实现中性粒细胞的特异性识别和内化。通过附着在中性粒细胞上，MPB NPs清除细胞内活性氧（ROS）并抑制病变部位的NET形成。重要的是，在动脉粥样硬化小鼠模型中，MPB NPs使动脉粥样硬化斑块的大小缩小了3.29倍，从22.53%降至6.85%，稳定了斑块并阻止其进展。这些发现表明，MPB NPs为动脉粥样硬化提供了一种有前景的治疗策略，并为治疗NET相关疾病提供了一个通用平台。
